Allurion Technologies
Natick, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and ov
Key facts
- Headquarters
- Natick, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (ALUR)
- Website
- allurion.com
- Company page
Recent activity at Allurion Technologies
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On July 21, 2026, Allurion Technologies, Inc. entered into an exchange agreement with various Stockholders to exchange 392,766 shares of its common stock for pre-funded warrants to purchase an equal number of shares. The Warrants, priced at $0.0001 each and exercisable immediately, feature a beneficial ownership limitation initially set at 9.99%. Key risks include automatic termination of the Warrants upon foreclosure events related to existing financing agreements. This transaction was executed under an exemption from registration, involving no commissions. The strategic impact reflects ongoing financial engagements with RTW Investments, LP and its affiliates, who hold significant influence due to prior stock ownership and financial interests in the Company.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On June 17, 2026, the Company announced a Reverse Stock Split through a press release. This event is significant as it affects the trading of the Company's common stock and public warrants. The announcement outlines various forward-looking statements regarding the implications of this stock split on regulatory compliance, market opportunities, and potential risks that may impact the Company's operations. Key considerations include the Company's ability to adhere to NYSE listing standards and the potential effects of global economic conditions on its business strategy.
- : SEC 8-K (8.01): On March 12, 2026, the Company issued a press release concerning the delisting notice of its Common Stock and Warrants from the NYSE, and its subsequent appeal of that determination. The trigger for these events was the recent FDA approval of the Allurion Gastric Balloon System, which initiated a strategic plan aimed at regaining compliance with NYSE listing standards or potentially relisting on the NYSE American. This plan includes strengthening the Company's balance sheet and funding the commercialization of the Allurion Smart Capsule in the U.S. The situation is in active management, and the details of the appeal along with compliance strategies have been shared with the NYSE and are currently being implemented.
- : SEC 8-K (8.01): On March 2, 2026, Allurion Technologies, Inc. announced via a press release the receipt of a Delisting Notice from the stock exchange, indicating that the exchange has determined to delist the company's stock. The company intends to appeal this delisting determination. This event is significant as it could affect the company's stock liquidity and market perception. The press release serves as an important communication to shareholders regarding the company's status and future plans related to the appeal.
- : SEC 8-K (1.01): On February 24, 2026, Allurion Technologies, Inc. entered into a warrant exercise inducement offer letter with certain holders of existing warrants issued between January and November 2025. The agreement stipulates that the exercise prices of these warrants will be reduced to $1.15 per share, and the holders will exercise their existing warrants for cash, purchasing a total of 2,659,565 shares of common stock, which is expected to generate approximately $3.0 million in gross proceeds for the Company. The company will also issue new warrants to purchase up to 5,319,130 shares of common stock, which will be exercisable following shareholder approval. Roth Capital Partners, LLC has been engaged as the financial advisor for this transaction and will receive a fee of 5% of the proceeds, along with up to $40,000 for legal fees and expenses.
- : SEC 8-K (7.01): On February 23, 2026, Allurion Technologies, Inc. announced via a press release that the U.S. Food and Drug Administration (FDA) granted PMA approval for the Allurion Gastric Balloon system, including the Allurion Smart Capsule. This system is designed to assist adults with obesity, specifically those aged 22 to 65 with a BMI between 30 and 40 who have attempted weight loss programs unsuccessfully. The press release implies significant strategic implications for Allurion, as this approval may enhance their market position in obesity treatments. Additionally, the communication outlines forward-looking statements regarding the commercialization of the product, indicating a potential shift in their operational focus and market strategy.
Allurion Technologies funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Private Equity | $5.0M |
| Feb 2025 | Venture | $7.4M |
| Dec 2023 | Pre-Seed | $123K |
| Feb 2017 | Venture | $19.0M |
Leadership
- Shantanu Gaur, Co-Founder & CEO
- John Harris, Sales Director
- Saleem Mustafa, Regional Sales Director MEA, Turkey & APAC
- Krishna Gupta, Director
- Neil Chheda, Director
- Jonathan Wecker, Executive Officer, Director
- Samuel Levy, Executive Officer, Director
- Shantanu Gaur, Executive Officer, Director
- Alexandra Stap, Vice President Global Marketing
- Camillo Docimo, Vice President Brazil Mexico Southern Central and Eastern Europe Sales
- Omar Ishrak, Director
- Benoit Chardon, Executive Officer
Verified email and direct lines for Allurion Technologies’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Allurion Technologies in the news
- Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum - Business Wire (Jun 02, 2026)
- Allurion Receives U.S. FDA Approval - Business Wire (Feb 23, 2026)
- Allurion Technologies Inc. (ALUR) stock price, news, quote and history - Yahoo Finance Australia (Oct 21, 2026)
- Allurion Technologies launches AI-native GLP-1 program for weight loss in the U.S. - MobiHealthNews (Nov 25, 2024)
- Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy - Business Wire (Mar 11, 2026)
- Allurion Technologies Inc. (ALUR) Stock Price, News, Quote & History - Yahoo! Finance Canada (Aug 04, 2023)
- Allurion Advances Plan to Re-List - Business Wire (Jun 17, 2026)
- Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity - Business Wire (Jan 21, 2025)
Companies similar to Allurion Technologies
- Treace · Biotechnology, Healthcare, Health Care, Manufacturing, Medical
- SynerFuse, Inc. · Biotechnology, Healthcare, Health Care, Manufacturing, Medical
- Monteris Medical · Biotechnology, Healthcare, Health Care, Manufacturing, Medical
- RIVANNA · Biotechnology, Healthcare, Health Care, Manufacturing, Medical
- Dror Ortho-Design · Biotechnology, Healthcare, Health Care, Manufacturing, Medical
About Allurion Technologies: questions and answers
What does Allurion Technologies do?
Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and ov
Where is Allurion Technologies headquartered?
Allurion Technologies is headquartered in Natick, Massachusetts, United States.
Has Allurion Technologies raised funding?
Yes. Fundz has recorded 4 funding events for Allurion Technologies. The most recent, Private Equity of $5.0M, was in Nov 2025.
Who leads Allurion Technologies?
Shantanu Gaur is a Co-Founder & CEO at Allurion Technologies.
What is the latest news on Allurion Technologies?
On Aug 24, 2026, SEC 8-K (5.02):
Is Allurion Technologies a public company?
Yes. Allurion Technologies is publicly traded under the ticker ALUR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy